Humana, Aledade team up to expand value-based care

FierceHealthcare | February 07, 2019

Humana, Aledade team up to expand value-based care
Insurance giant Humana is teaming with Bethesda, Maryland-based primary care consulting company Aledade to expand access to value-based care for its Medicare Advantage members in three states.  Physicians working in Aledade’s accountable care organizations in Pennsylvania, Louisiana and West Virginia will be able to take advantage of technological tools, data and other resources from both Aledade and Humana under the agreement, according to an announcement. Louisville, Kentucky-based Humana has made value-based care a central focus over the past year and in April launched its Hospital Incentive Program with the goal of reducing duplicative services and readmissions. Cleveland Clinic Florida and Georgia’s WellStar Health System were among the first providers to jump into the program.

Spotlight

From a patient perspective, hub services can often be a lifeline to managing complicated, chronic conditions. Creating a solution that supports patients who rely on middle-ground  specialty medications is a necessity for an area that is becoming a larger part of the overall pharmaceutical landscape. The Hub-Lite model offers an efficient approach to drugs whose cost or pattern of treatment don’t justify the expense of full-edged patient services. Pharmaceutical brands target different therapeutic areas, face a variety of challenges and have diverse needs.


Other News
INSURANCE

Exela Expands PCH Global Solution with Leading Healthcare Insurer

Exela Technologies | January 12, 2022

Exela Technologies, Inc. (“Exela”)today announced that it continues to expand its relationship with a leading health insurance organization that spans almost two decades. This customer continues to accelerate deployment of Exela’s PCH Global platform to speed up their digital transformation and improve both the member and provider experience. The latest expansion is valued at $6.2 million of additional contract value revenue. Exela continues to invest in expanding PCH Global’s capabilities to provide a cloud hosted solution with one of the best edit resolutions for healthcare claims. This extension of deployment marks another milestone in the value proposition of the PCH Global platform to digitally connect members, providers and insurance companies to enable clean claims, payment transparency and digital appeals. PCH Global’s cloud network also offers increased scalability, the highest uptime and best business continuity protections. PCH Global has robust data analytics which are continually improving as Exela processes more and more data. Additionally, PCH Global’s improved data analytics can be accessed via a self-service model. “We are proud of our long standing partnership and privileged to be part of customer’s digital transformation journey. Adoption of our PCH Global platform continues to address healthcare industry’s goal to deliver most efficient, cost effective and best healthcare to the members.” Suresh Yannamani, President of Exela About Exela Technologies Exela Technologies is a business process automation (BPA) leader, leveraging a global footprint and proprietary technology to provide digital transformation solutions enhancing quality, productivity, and end-user experience. With decades of experience operating mission-critical processes, Exela serves a growing roster of more than 4,000 customers throughout 50 countries, including over 60% of the Fortune® 100. Utilizing foundational technologies spanning information management, workflow automation, and integrated communications, Exela’s software and services include multi-industry, departmental solution suites addressing finance and accounting, human capital management, and legal management, as well as industry-specific solutions for banking, healthcare, insurance, and the public sector. Through cloud-enabled platforms, built on a configurable stack of automation modules, and over 17,500 employees operating in 23 countries, Exela rapidly deploys integrated technology and operations as an end-to-end digital journey partner.

Read More

DIGITAL HEALTHCARE

AMIH Announces Expansion of EPIQ MD’s Telehealth Platform and Services

Epiq MD | January 21, 2022

American International Holdings Corp., adiversified holding company that develops, acquires and operates technology-based health and wellness companies, today announced that its subsidiaryEPIQ MD, Inc.,has expanded the availability of its telehealth service offerings to thirteen (13) states across the United States. EPIQ MD, Inc., the convergence of primary care, mental health, preventative, and wellness programs through an online healthcare platform, announced its original launch and arrival in four statesback in September of 2021. Now with the introduction of their platform throughout the Southern U. S. border, EPIQ MD is directly on pace to achieve its goal of covering all 50 U. S. states by the year-end 2022 “This expansion of EPIQ MDs telehealth services and offerings across the Southern border of the United States further cements the sentiment that EPIQ MD has held since its official launch in September 2021”, comments Jacob Cohen, President and CEO of American International Holdings Corp. "Our vision is to be an essential service for millions of working families and individuals who currently don’t have any other viable options. Having access to a doctor or mental health professional 24/7/365 represents a crucial advancement in overall quality of life and we simply believe that the more eyes that are opened to EPIQ MD, the more we will be able to grow and expand.” EPIQ MD Director, Michael Ladner EPIQ MD is not simply bringing their expansive array of healthcare services to additional states, but are excited about their most recent introduction of Epiq PAWsand Epiq LUX. Epiq PAWs being EPIQ MD’s virtual care add-on tailored towards furry family members (a/k/a pets), and Epiq LUX being a wide-ranging discount program offering savings on a variety of ancillary medical services, including but not limited to, Laboratory Services, Dental, Vision, Chiropractic, Imaging and Diabetes/Home Medical Supplies. The Company believes that this current footprint represents a great mix of both urban and rural geographic locations, filled with demographics ripe for our primary care and mental health services. Seven of the states listed herein as our coverage area are also within the “top 10 states with the highest percentage of uninsured Americans”, according to the U.S. Central Bureau. While EPIQ MD envisions its platform spreading steadily throughout the United States as the year 2022 progresses, our strategy is to target the areas wherein we can make the biggest difference via our service offering. About EPIQ MD, Inc. EPIQ MD believes that everyone deserves to live an epic life. It is the convergence of primary medical and mental health care, preventative care and wellness programs - on one digital platform, in a single offering. Conceived as a digital telemedicine-based business from the start, its core mission is to bring these services and knowledge to the 80 million Americans who are uninsured or underinsured. Its telemedicine platform provides services such as primary care, medical advisory, ask a medical expert, mental health services, discounted diagnostic lab services, prescription discount program, nutritional counseling and much more. Today Epiq MD is active and operational in Alaska, Georgia, Illinois, Texas, Arizona, New Mexico, Colorado, Louisiana, Mississippi, Alabama, Florida, Nevada and Utah. About American International Holdings Corp. American International Holdings Corp. is an investor, developer and asset manager of diversified, synergistic health and wellness businesses. Today, the AMIH portfolio encompasses telemedicine and other virtual health platforms, affordable subscriber-based primary care and concierge medicine plans, preventative care solutions and wellness related assets such as mental & behavioral health services, as well as its own proprietary life coaching platform. AMIH markets its various services through direct-to-consumer and business-to-business distribution channels. AMIH’s focus is on bringing to market technologies and solutions that advance the quality of life for the global community.

Read More

MEDICAL DEVICES

BD Acquires Scanwell Health, Inc. to Expand and Scale Digital At-Home Testing

BD | December 22, 2021

BD (Becton, Dickinson and Company), a leading global medical technology company, today announced it has completed the acquisition of privately held Scanwell Health Inc., a leader in smartphone-enabled at-home medical tests.BD collaborated with Scanwell to develop the app used with the recently launched BD Veritor™ At-Home COVID-19 Test, the first at-home COVID-19 test that uniquely uses a smartphone camera and app to capture and interpret results, eliminating the human subjectivity in other visually read at-home antigen tests. Scanwell will become the foundational digital platform upon which BD plans to develop at-home diagnostic tests for a range of infectious diseases including COVID-19/influenza A+B, group A strep and additional menu for detecting infections and managing chronic disease. "The COVID-19 pandemic has accelerated the shift to new care settings, and BD is ready to deliver a smart, connected at-home diagnostic ecosystem to support traditional and telehealth providers and consumers. This acquisition will enable us to expand and scale our digital capabilities in-house to speed time to market for transformative at-home solutions now and in the future." Dave Hickey, president of Life Sciences for BD The Scanwell app is a key differentiator in the market for at-home COVID-19 testing. To date, no other company uses the phone's camera to capture the image of the test that is then analyzed and interpreted by the app. Other COVID-19 home tests use smartphones as part of their process, but BD Veritor™ At-Home COVID-19 Test is the first and only test to use the smartphone as the analyzer to digitally interpret the test results and provide a definitive POSITIVE or NEGATIVE digital display of testing results. The app also has the capabilities to securely store and report test results to organizations, including businesses, public health authorities and schools. The results of tests are stored in the app and can be referenced and displayed at any time by simply logging into the app. Terms of the transaction were not disclosed. The transaction is expected to be immaterial to BD's fiscal 2022 financial results. Scanwell financial results will be reported under the Integrated Diagnostic Solutions business within the Life Sciences segment. About the BD Veritor™ At-Home COVID-19 Test The BD Veritor™ At-Home COVID-19 Test has not been FDA cleared or approved; but has been authorized by FDA under Emergency Use Authorization (EUA). This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of IVDs for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner. About BD BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.

Read More

HEALTH TECHNOLOGY

CareCloud Launches All-New Interoperability and Data Exchange Solution for Healthcare Organizations

CareCloud, Inc | December 17, 2021

CareCloud, Inc., a leader in healthcare technology solutions for medical practices and health systems nationwide has released CareCloud Connector, a next-generation interface and data management engine, and the first product within its CareCloud Conductor suite. CareCloud Connector enables healthcare organizations with ready-to-use integrations that improve data management and deployment speed, while offering better interface visibility and control. “We have been a leading healthcare IT innovator for almost two decades, providing solutions that improve financial, clinical, and patient outcomes, at scale, and a partner to a wide array of healthcare organizations. Today we are introducing our proprietary, turn-key integration technology platform to help healthcare ecosystem partners leverage the same tools we ourselves use to manage our business across hundreds of unique integrations spanning thousands of locations.” Hadi Chaudhry, CEO and President, CareCloud As the U.S. healthcare industry’s data exchange regulations continue to evolve and vendors prepare to comply with provisions in the Cures Act, legacy integration tools will hinder progress. CareCloud Connector provides a seamless, scalable, and centralized platform with APIs, allowing healthcare IT vendors, medical billing organizations, and digital health companies to overcome interoperability challenges and effectively manage data integration and transmission hurdles. Connector includes a library of industry-tested, ready-to-use integrations, interfaces, and customizable tools in a convenient SaaS offering. "As one of the industry’s first true libraries of plug-and-play integration and customizable tools, CareCloud Connector transforms laborious developmental projects into simple and secure activations,” said Adeel Sarwar, Chief Technology Officer, CareCloud. “Connector makes data exchange and management simple and cost-effective for industry participants.” "Healthcare organizations often struggle with managing hundreds of interface requests and data migration challenges. Couple this with the complexities of new regulatory requirements embedded in the Cures Act and you set the stage for a solution like Connector,” said David Botero, Director of Integrations, CareCloud. “Connector allows us to close interoperability gaps for industry participants. We are proud to be a leader in integration consolidation, empowering health organizations and service providers to comply with new interoperability requirements while saving money and resting easy, knowing that a leading publicly-traded healthcare IT vendor is taking care of the hard work for them." CareCloud Connector is the first solution launching under CareCloud’s new technology suite, CareCloud Conductor. Conductor is a family of technologies designed to support interoperability, connectivity, and data transformation. CareCloud plans to unveil more products in the Conductor suite in 2022 with the launch of additional innovative solutions to support the growing prominence of health IT developers and investments in digital health. About CareCloud CareCloudbrings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs.

Read More

Spotlight

From a patient perspective, hub services can often be a lifeline to managing complicated, chronic conditions. Creating a solution that supports patients who rely on middle-ground  specialty medications is a necessity for an area that is becoming a larger part of the overall pharmaceutical landscape. The Hub-Lite model offers an efficient approach to drugs whose cost or pattern of treatment don’t justify the expense of full-edged patient services. Pharmaceutical brands target different therapeutic areas, face a variety of challenges and have diverse needs.

Resources